Analysts Offer Insights on Healthcare Companies: Vertex Pharmaceuticals (VRTX) and Apellis Pharmaceuticals (APLS)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Vertex Pharmaceuticals (VRTX – Research Report) and Apellis ...
Business Insider6d
Vertex Pharmaceuticals pursuing research-stage T1Dd programs
Zimislecel, Vertex’s investigational fully differentiated islet cell therapy with standard immunosuppression, is in the Phase 3 portion of the Phase 1/2/3 study in patients with T1D with severe ...
Tax Tech Market worth $36.72 billion by 2030- Exclusive Report by MarketsandMarkets
The global Tax Tech Market will grow from USD 18.53 billion in 2024 to USD 36.72 billion by 2030 at a compounded annual growth rate (CAGR) ...
pharmaphorum4d
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
unite2d
10 Best AI Logo Generators (April 2025)
Unite.AI is committed to rigorous editorial standards. We may receive compensation when you click on links to products we review. Please view our affiliate disclosure. Creating a strong brand identity ...